Can IceCure Medical turn 70% ProSense installation growth into durable breast cancer revenue?
IceCure Medical’s FDA-authorised breast cancer cryoablation platform is gaining United States installations, but narrow eligibility, postmarket evidence requirements and heavy dilution complicate the small-cap investment case.
